Inclisiran is a small interfering RNA therapeutic agent classified as an antisense oligonucleotide used to reduce low-density lipoprotein cholesterol levels in patients with heterozygous or severe homozygous… Read more
Inclisiran is a small interfering RNA therapeutic agent classified as an antisense oligonucleotide used to reduce low-density lipoprotein cholesterol levels in patients with heterozygous or severe homozygous familial hypercholesterolaemia. By targeting the messenger RNA of PCSK9, this drug prevents the degradation of LDL receptors, facilitating more effective cholesterol clearance from the bloodstream. To support the rigorous demands of pharmaceutical research, analytical laboratories utilize high-quality Inclisiran reference standards, including associated impurities, metabolites, and stable isotope-labelled compounds. These materials are critical for accurate impurity profiling, method validation, and bioanalytical quantification. By providing essential tools for the characterization of both the active pharmaceutical ingredient and its degradation products, these reference compounds enable precise quality control throughout the drug development lifecycle and ensuring compliance with stringent regulatory standards for complex oligonucleotide therapies.